UCBL, FRANCE(M) : ProfileXpert Genomics core facility (www.profilexpert.fr) founded in 2003 by Prof. Joel LACHUER is one of the 20 official national core facilities in France and belongs to the University of Lyon (France). The platform is located at the medicine faculty of Lyon. The activity of the laboratory is dedicated to the analysis of biological systems by using genomics, transcriptomics, epigenomics, and metagenomics approaches at the resolution of whole tissues or single cell (Eukaryote)

Joel LACHUAR

Professor Joel Lachuer, 63, is director of the profilexpert genomics platform (technological platform of the University of Lyon 1 belonging to the France genomic network and Gis-Ibisa) and creator of the service company Viroscan3D specialized in genomics and infectiology.  After graduate studies at the Pierre and Marie Curie University in Paris, he completed a PhD in Neuroscience in Lyon and then was a post-doctoral researcher for the Roussel Uclaf company. He was then recruited as assistant professor at the Lyon University in the laboratory of extreme environment physiology. During this period, he implemented various genomics technologies, including the first DNA microarrays (1993).  In 1999, he joined Dr. C Barlow’s Genetics Laboratory at the Salk Institute for Biological Studies in San Diego (USA) as a visiting scientist to develop, in partnership with one of the inventors of the Affymetrix technology, techniques for analyzing microquantities of RNA. In 2002, upon his return to France he created the genomics platform profilexpert (www.profilexpert.fr) and in 2012 the company Viroscan3D. In 2024, he was co-winner of the Innovation Prize awarded by the Ministry of Research. He teaches genomics at the university and is responsible for the professional degree in genomics (IUT Lyon1)

Julient FORET

Dr Julien Fouret a obtenu sa thèse en Phylogénomique Comparative à l’École Normale Supérieure de Lyon en 2018. Durant son doctorat, il a travaillé au sein de la Plateforme ProfileXpert pour résoudre l’assemblage de novo de la chauve souris géante d’Inde afin de mieux comprendre son système immunitaire. Après son doctorat, il a été post-doct, puis directeur de la Data Science chez Signia Therapeutics de 2019 à 2023, se concentrant sur le criblage de médicaments in silico en utilisant des données multi-omiques et l’IA. À partir de 2024, il est responsable de la R&D chez Nexomis, une plateforme de recherche bioinformatique à l’Université Claude Bernard Lyon 1.